Product Description
Mechanisms of Action: Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Myrexis
Company Location: NEW YORK NY 10020
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Glioblastoma|Melanoma
Phase 1: Brain Cancer|Alzheimer Disease|Amyotrophic Lateral Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AAAS4926 | P1 |
Recruiting |
Alzheimer Disease|Amyotrophic Lateral Sclerosis |
2024-09-01 |
|
| MPC-6827-021 | P2 |
Completed |
Glioblastoma |
2012-03-01 |
|
| MPC-6827-019 | P2 |
Completed |
Glioblastoma |
2011-07-01 |
|
| MPC-6827-07-004 | P2 |
Unknown status |
Glioblastoma |
2010-10-01 |